193 related articles for article (PubMed ID: 37682461)
1. Comparison of the Latin America Regulation Landscape and International Reference Health Authorities to Hasten Drug Registration and Clinical Research Applications.
Argotti U; Leyens L; Lisbona C; López P; Alonso-Orgaz S; Nevado A; Cozzi V
Ther Innov Regul Sci; 2023 Nov; 57(6):1287-1297. PubMed ID: 37682461
[TBL] [Abstract][Full Text] [Related]
2. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations.
Ghadanian M; Schafheutle E
Ther Innov Regul Sci; 2024 Jan; 58(1):79-113. PubMed ID: 37861859
[TBL] [Abstract][Full Text] [Related]
3. Registration pathways to accelerate regulatory assessment of innovative medicines in Latin America.
Padua A; Partika L; Bonamici D; Rahal Cabello J; Kohiyama C; Spinardi P; Castro A; Rolim A; Souto F
J Public Health Policy; 2020 Dec; 41(4):481-495. PubMed ID: 32879437
[TBL] [Abstract][Full Text] [Related]
4. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
5. Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs.
Hata T; Nakamura K; Yonemori K; Noguchi E; Watanabe M; Sohn J; Lu YS; Yap YS; Tamura K; Fujiwara Y
Clin Transl Sci; 2021 May; 14(3):1015-1025. PubMed ID: 33382914
[TBL] [Abstract][Full Text] [Related]
6. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
7. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia.
Hwang TJ; Kesselheim AS; Tibau A; Lee CC; Vokinger KN
JCO Oncol Pract; 2022 Sep; 18(9):e1522-e1532. PubMed ID: 35731996
[TBL] [Abstract][Full Text] [Related]
8. Harmonization of individual case safety reports transmission requirements among PAHO reference authorities: a review of their current regulation.
Lomeli-Silva A; Contreras-Salinas H; Barajas-Virgen MY; Romero-Lopez MS; Rodríguez-Herrera LY
Ther Adv Drug Saf; 2024; 15():20420986241228119. PubMed ID: 38323190
[TBL] [Abstract][Full Text] [Related]
9. Comparative Expedited Regulatory Programs of U.S Food & Drug Administration and Project Orbis Partners.
Hotaki LT; Shrestha A; Bennett MP; Valdes IL; Lee SH; Wang Y; Spillman D; MacAulay T; Hunt M; Gervais J; Mafi M; Panetta V; Looi YH; Shum M; Atiek E; Meincke R; Rohr UP; Ainbinder D; Boehm-Cagan A; Luxenburg O; Cerqueira MR; Mouawad LS; Thees MFRES; Prasad K; de Claro RA
Ther Innov Regul Sci; 2023 Jul; 57(4):875-885. PubMed ID: 37072651
[TBL] [Abstract][Full Text] [Related]
10. Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
Rivera VM
Neurol Ther; 2019 Dec; 8(2):177-184. PubMed ID: 31313222
[TBL] [Abstract][Full Text] [Related]
11. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.
Nagai S; Ozawa K
Int J Hematol; 2016 Jul; 104(1):73-84. PubMed ID: 27084259
[TBL] [Abstract][Full Text] [Related]
12. Regulatory reliance to approve new medicinal products in Latin American and Caribbean countries.
Durán CE; Cañás M; Urtasun MA; Elseviers M; Andia T; Vander Stichele R; Christiaens T
Rev Panam Salud Publica; 2021; 45():e10. PubMed ID: 33859678
[TBL] [Abstract][Full Text] [Related]
13. The Investigators' Brochure: a comparison of the draft international conference on harmonisation guideline with current Food and Drug Administration requirements.
Cocchetto DM
Qual Assur; 1995 Dec; 4(4):240-6. PubMed ID: 8890349
[TBL] [Abstract][Full Text] [Related]
14. An Analysis of Regulatory Timing and Outcomes for New Drug Applications Submitted to Swissmedic: Comparison With the US Food and Drug Administration and the European Medicines Agency.
Dörr P; Wadworth A; Wang T; McAuslane N; Liberti L
Ther Innov Regul Sci; 2016 Nov; 50(6):734-742. PubMed ID: 30231740
[TBL] [Abstract][Full Text] [Related]
15. Regulatory advice and drug development--a case study in negotiating with regulators.
Seldrup J
Stat Med; 2011 Jun; 30(13):1628-35. PubMed ID: 21365671
[TBL] [Abstract][Full Text] [Related]
16. Regulatory Pathways Supporting Expedited Drug Development and Approval in ICH Member Countries.
Franco P; Jain R; Rosenkrands-Lange E; Hey C; Koban MU
Ther Innov Regul Sci; 2023 May; 57(3):484-514. PubMed ID: 36463352
[TBL] [Abstract][Full Text] [Related]
17. Perspectives for licensing vaccines in Mexico.
Padron-Regalado E; Medina-Rivero E
Vaccine; 2022 Aug; 40(34):4979-4985. PubMed ID: 35835630
[TBL] [Abstract][Full Text] [Related]
18. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
[TBL] [Abstract][Full Text] [Related]
19. Regulatory reliance pathways during health emergencies: enabling timely authorizations for COVID-19 vaccines in Latin America.
van der Zee IT; Vreman RA; Liberti L; Garza MA
Rev Panam Salud Publica; 2022; 46():e115. PubMed ID: 36060200
[TBL] [Abstract][Full Text] [Related]
20. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustí A
Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
